Literature DB >> 21521431

Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme.

Claire Anderson1, Alison Gifford, Anthony Avery, Heather Fortnum, Elizabeth Murphy, Janet Krska, Christine Bond.   

Abstract

OBJECTIVES: The aim of this study, which was part of the first independent evaluation of patient reporting of adverse drug reactions (ADRs) to the Yellow Card Scheme, was to observe the three reporting systems (paper, internet and telephone) 'in use' in a simulated setting to identify aspects which facilitated or hindered reporting.
METHODS: Forty adult participants were recruited from the general public using posters in pharmacies and a press article, and from a pool of volunteer simulated patients maintained by University of Nottingham medical and pharmacy schools. The participants, in seven groups that met at different times, were asked to 'think aloud,' as they were individually observed completing the reporting process for the paper and internet system, highlighting their thoughts and any issues encountered. They were asked to talk about their experience of reporting immediately after they had reported by telephone. Data from the field notes were analysed thematically and supplemented with relevant information from digital audio recordings.
CONCLUSIONS: Usability testing using the 'think aloud' approach worked well and identified areas of the Yellow Card reporting system which could be improved. Whilst the three methods of reporting available to the public are all reasonably 'fit for purpose', there were many suggestions identified for improving ease of completion and data quality, especially for the internet system. When systems for reporting of ADRs are designed, they should be tested by potential users before they are launched, so that potential problems are identified in advance.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21521431      PMCID: PMC5060635          DOI: 10.1111/j.1369-7625.2011.00686.x

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  4 in total

1.  A comparison of usability methods for testing interactive health technologies: methodological aspects and empirical evidence.

Authors:  Monique W M Jaspers
Journal:  Int J Med Inform       Date:  2008-11-29       Impact factor: 4.046

Review 2.  Usability testing: a review of some methodological and technical aspects of the method.

Authors:  J M Christian Bastien
Journal:  Int J Med Inform       Date:  2009-04-02       Impact factor: 4.046

3.  The think aloud method: a guide to user interface design.

Authors:  Monique W M Jaspers; Thiemo Steen; Cor van den Bos; Maud Geenen
Journal:  Int J Med Inform       Date:  2004-11       Impact factor: 4.046

4.  Computerized patient education in kidney transplantation: testing the content validity and usability of the Organ Transplant Information System (OTIS).

Authors:  Petra Schäfer-Keller; Michael Dickenmann; Donna L Berry; Jürg Steiger; Andreas Bock; Sabina De Geest
Journal:  Patient Educ Couns       Date:  2008-06-02
  4 in total
  4 in total

Review 1.  Experiences with adverse drug reaction reporting by patients: an 11-country survey.

Authors:  Florence van Hunsel; Linda Härmark; Shanthi Pal; Sten Olsson; Kees van Grootheest
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Editorial.

Authors:  Jonathan Tritter
Journal:  Health Expect       Date:  2012-12       Impact factor: 3.377

3.  Awareness and compliance with pharmacovigilance requirements amongst UK oncology healthcare professionals.

Authors:  Rebecca J Thorne; Rosanne J Bruggink; Stephen J Kelly; Sarah Jl Payne; Simon J Purcell; David A Montgomery
Journal:  Ecancermedicalscience       Date:  2018-02-08

4.  What can we learn from parents about enhancing participation in pharmacovigilance?

Authors:  Janine Arnott; Hannah Hesselgreaves; Anthony J Nunn; Matthew Peak; Munir Pirmohamed; Rosalind L Smyth; Mark A Turner; Bridget Young
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.